SIGN UP FOR UPDATES!
Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
ENGLEMED
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BOOKS AND GIFTS THIS WAY!
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
SEARCH THIS SITE
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
FreeDigitalPhotos
www.freedigitalphotos.net
FreeWebPhotos
www.freewebphoto.com
FROM OUR NEWS FEEDS
Mixed access to home palliative care - study
Fri March 22nd - Access to palliative care at home for terminally ill patients depends heavily on the diagnosis, researchers say today. More
RECENT COMMENTS
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote:
https://epidemicj17.imascientist.org.uk/2017/06/21... on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...
On 12/03/2017 Steph wrote:
The photo you have paired with this article is its... on 'Fat shaming' limits...
OTHER NEWS FEEDS OF INTEREST
ENGLEMED HEALTH NEWS

ACEIs linked to increased risk of lung cancer

Thursday October 25th, 2018

Some blood pressure drugs have been linked to an increased risk of lung cancer, according to a new observational study.

The research, led by McGill University, Canada, found that angiotensin converting enzyme inhibitor drugs (ACEIs) – particularly if used for more than five years – is associated with the risk when compared with angiotensin receptor blockers (ARBs).

Writing in The BMJ, the scientists say that although the risk for individual patients is modest, ACEIs are widely prescribed, which means the “small relative effects” could translate into “large absolute numbers of patients at risk for lung cancer.”

The findings “should be replicated in other settings, particularly among patients exposed for longer durations”, they add.

In what is the largest study to assess this specific association, Professor Laurent Azoulay analysed UK primary care records for nearly one million adults who started taking a new antihypertensive drug between 1995 and 2015 to establish if there is an association, after previous research reported inconsistent results.

The patients, none of whom had had any previous cancer, were followed up for an average of 6.4 years, during which time 7,952 cases of lung cancer were identified – a rate of 1.3 per 1000 person years.

After taking account of factors that could potentially influence the findings, such as smoking history, ACEI use was associated with an overall 14% increased risk of lung cancer compared with ARBs – 1.6 cases per 1000 person years compared with 1.2.

The association increased the longer the ACEIs were taken and for those who used them for more than 10 years, there was a 31% increased risk.

The researchers say that because it is an observational study, they can neither draw any firm conclusions about cause and effect nor rule out the possibility that other unmeasured factors, such as socioeconomic differences, diet, and family history of lung cancer, may have affected the results.

However, the findings in the study were consistent after further analyses to test the strength of the results.

The researchers have recommended additional studies, with long term follow-up, to investigate the effects of these drugs on incidence of lung cancer.

British Heart Foundation medical director Professor Sir Nilesh Samani called for more research.

He said: “ACE inhibitors have been prescribed for many years to treat heart failure and high blood pressure, and are undeniably life-saving. The suggested link to lung cancer is a surprise, and based on an observational study.

“While the authors have tried to look for other reasons for the link, they accept there’s always the possibility it’s down to factors they didn’t measure.”

Hicks B, Filion K, Yin H et al. Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study. The BMJ. October 2018. BMJ 2018;363:k4209. http://dx.doi.org/10.1136/bmj.k4209

http://www.bmj.com/content/363/bmj.k4209

Tags: Cancer | Heart Health | North America | Pharmaceuticals | Respiratory | UK News

Printer friendly page Printer friendly page

Comment on this article:

Name:
Email:
Comment:
<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)
CATEGORIES